Trial Profile
Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jul 2015
Price :
$35
*
At a glance
- Drugs BMS 963272 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 21 Jul 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 21 May 2015 Planned End Date changed from 1 Apr 2015 to 1 May 2015, as reported by ClinicalTrials.gov.
- 21 May 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015, as reported by ClinicalTrials.gov.